原发性肝癌生物标志物与中医微观辨证学创新和发展  

Innovation and Development of Biomarkers of Primary Liver Cancer and Microscopic Differentiation of TCM

作　　者：冯文杏 周小舟 张卫 韩志毅 孙新锋 马文峰 FENG Wenxing;ZHOU Xiaozhou;ZHANG Wei;HAN Zhiyi;SUN Xinfeng;MA Wenfeng(The Fourth Clinical College of Guangzhou Universtiy of Chinese Medicine, Shenzhen 518033, China)

机构地区：[1]广州中医药大学第四临床医学院

出　　处：《中医药信息》2019年第3期60-63,共4页Information on Traditional Chinese Medicine

基　　金：深圳市科技计划项目(No.JCYJ20170817094901026,JCYJ20160428181031086)

摘　　要：肝细胞癌(HCC)是世界上第六大常见的癌症,并且是第四个癌症相关死亡原因。尽管在HCC诊断处理上取得了重大进步,但仅1/3的新确诊患者适合于治愈性治疗。随着技术的进步和对HCC生物学的理解增加,不断有新的标志物被发现。由于具有非侵入性、目的性及能反复评估的潜力,血清标志物是非常有潜力监测和早期诊断HCC的工具。在科学发展的契机下,多学科交叉对这一疾病的早期诊断、预防和预后预测模式与中医辨证论治思想在某些方面有相同之处,或可为中医对疾病整体观与微观辨证之间的关系架起研究的桥梁,从而发展建立客观可行的中医辨证模式,亦是中医传承和创新发展的重要手段。Hepatocellular carcinoma(HCC) represents the sixth most common cancer and the fourth leading cause of cancer-related mortalities in the world. Although significant progress has been made in the diagnosis and treatment of HCC, only a third of newly diagnosed patients are eligible for curative treatment. With the advancement of technology and understanding of HCC biology, new biomarkers have been found. Thanks to their non-invasive, purposeful and repeated evaluative characteristics, serum markers are more potential tools for surveillance and early diagnosis of HCC. With the development of science, multidisciplinary cross share the same effect with the TCM syndrome differentiation in early diagnosis, prevention and prognosis of HCC;it builds a bridge to study the relationship between the theory of holism and microcosm. Consequently we can establish an objective and feasible syndrome differentiation model, which is also an important means of inheritance and innovation of TCM.

关 键 词：肝细胞癌(HCC) 生物标志物 中医微观辨证 

分 类 号：R735.7[医药卫生—肿瘤]